Want to see IN:DCAL full AI Analyst Report?
DCAL Stock Chart & Stats
₹255.15
-₹14.00(-4.80%)
At close: 4:00 PM EST
₹255.15
-₹14.00(-4.80%)
Day’s Range― - ―
52-Week Range₹129.00 - ₹305.50
Previous CloseN/A
Volume578.20K
Average Volume (3M)11.12K
Market Cap
₹23.72B
Enterprise Value₹40.88B
Total Cash (Recent Filing)₹10.07B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)34.8
Beta1.38
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.11%
Share Statistics
EPS (TTM)4.35
Shares Outstanding156,783,100
10 Day Avg. Volume8,670
30 Day Avg. Volume11,117
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.69
P/FCF Ratio26.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified CDMO Business ModelDCAL combines pharmaceutical CDMO services with specialty chemicals, giving it exposure to multiple customer needs and end markets. Its capabilities span development, scale-up and commercial manufacturing, which can support deeper customer relationships and create opportunities for repeat revenue as projects advance.
Positive Operating Cash FlowConsistently positive operating cash flow indicates that the core business has been converting activity into cash despite volatility in reported earnings. This supports ongoing operations and provides a more durable funding base for investment than earnings alone, although free-cash-flow consistency remains important.
Manageable Leverage And Equity BaseModerate leverage and a sizable equity base provide DCAL with some financial resilience as it operates across pharmaceutical manufacturing and specialty chemicals. This balance-sheet foundation can help absorb operating variability and preserve strategic flexibility, even though debt has been increasing over time.
Bears Say
Volatile ProfitabilityLarge year-to-year swings in profitability reduce confidence that recent earnings recovery represents a stable earnings base. Inconsistent margins can make planning and capital allocation more difficult, while weaker periods may limit internally funded investment and reduce the predictability of shareholder returns.
Uneven Free-cash-flow ConversionThe recovery in free cash flow is constructive, but earlier negative periods and sharply changing growth rates show that operating cash has not translated consistently into discretionary cash. This can constrain debt reduction, reinvestment and other capital allocation choices when spending needs rise.
Rising Debt And Weak ReturnsIncreasing debt alongside weak or negative returns on equity suggests that additional capital has not consistently produced attractive earnings. If this pattern persists, interest obligations and a larger capital base could weigh on financial flexibility and make future growth more dependent on improved execution.
Dishman Carbogen Amcis Ltd. News
DCAL FAQ
What was Dishman Carbogen Amcis Ltd.’s price range in the past 12 months?
Dishman Carbogen Amcis Ltd. lowest stock price was ₹129.00 and its highest was ₹305.50 in the past 12 months.
What is Dishman Carbogen Amcis Ltd.’s market cap?
Dishman Carbogen Amcis Ltd.’s market cap is ₹23.72B.
When is Dishman Carbogen Amcis Ltd.’s upcoming earnings report date?
Dishman Carbogen Amcis Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 19 days.
How were Dishman Carbogen Amcis Ltd.’s earnings last quarter?
Dishman Carbogen Amcis Ltd. released its earnings results on Aug 14, 2026. The company reported -₹0.369 earnings per share for the quarter.
Is Dishman Carbogen Amcis Ltd. overvalued?
According to Wall Street analysts Dishman Carbogen Amcis Ltd.’s price is currently Overvalued.
Does Dishman Carbogen Amcis Ltd. pay dividends?
Dishman Carbogen Amcis Ltd. pays a Notavailable dividend of ₹0.2 which represents an annual dividend yield of 0.11%. See more information on Dishman Carbogen Amcis Ltd. dividends here
What is Dishman Carbogen Amcis Ltd.’s EPS estimate?
Dishman Carbogen Amcis Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dishman Carbogen Amcis Ltd. have?
Dishman Carbogen Amcis Ltd. has 156,783,100 shares outstanding.
What happened to Dishman Carbogen Amcis Ltd.’s price movement after its last earnings report?
Dishman Carbogen Amcis Ltd. reported an EPS of -₹0.369 in its last earnings report. Following the earnings report the stock price went down -4.081%.
Which hedge fund is a major shareholder of Dishman Carbogen Amcis Ltd.?
Currently, no hedge funds are holding shares in IN:DCAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dishman Carbogen Amcis Ltd.
Established in 1983 and headquartered in Ahmedabad, India, Dishman Carbogen Amcis Limited provides specialized contract research and manufacturing solutions to the worldwide pharmaceutical sector. The company operates through two main business segments: Contract Research and Manufacturing Services (CR&MS), and Marketable Molecules. Beyond its core services, it manufactures and distributes an extensive portfolio of products, including bulk drugs, chemical intermediates, various phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D derivatives, and fine chemicals. Additionally, its offerings encompass personal care products like hand and body washes, sanitizers, and antiseptics, as well as a range of pharmaceutical and cosmetic formulations, including generic and highly potent active pharmaceutical ingredients. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Technical Analysis
Biocon Limited
―
Blue Jet Healthcare Limited
―
Concord Biotech Ltd.
―
Syngene International Ltd.
―
OneSource Specialty Pharma Limited
―